Stockscreener 앱 받기
12.51
9.22%
-1.27
전일 마감가:
$13.78
열려 있는:
$14.4
하루 거래량:
180.71K
Relative Volume:
8.88
시가총액:
$98.24M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.08%
1개월 성능:
+14.25%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$12.00
$23.76
1주일 범위
$12.00
$23.76
52주 변동 폭
$10.00
$23.76
Jatt Ii Acquisition Corp Stock (JATT) Company Profile
명칭
Jatt Ii Acquisition Corp
전화
201-688-0364
주소
C/O APPLEBY GLOBAL SERVICES (CAYMAN) LTD, GEORGE TOWN
Compare JATT vs XXI, LION, UMAC, CCXI, DMII
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JATT
Jatt Ii Acquisition Corp
|
12.59 | 105.50M | 0 | 0 | 0 | 0.00 |
XXI
Twenty One Capital Inc
|
6.445 | 3.12B | 0 | 4.35M | 456.40K | 0.3397 |
LION
Lionsgate Studios Corp
|
11.46 | 3.45B | 2.63B | -175.60M | 11.40M | -0.7173 |
UMAC
Unusual Machines Inc
|
27.38 | 1.41B | 17.25M | -5.64M | -40.16M | -0.3337 |
CCXI
Churchill Capital Corp Xi
|
14.65 | 813.22M | 0 | 0 | 0 | 0.0647 |
DMII
Drugs Made In America Acquisition Ii Corp
|
10.14 | 644.64M | 0 | 8.58M | -1.11M | 0.134 |
Jatt Ii Acquisition Corp 주식(JATT)의 최신 뉴스
Balyasny Asset Management L.P. Initiates Position in JATT II Acq - GuruFocus
ADAR1 Capital Management (JATT) discloses 5.4% beneficial stake in JATT II - Stock Titan
JATT II Acquisition Corp. (JATT) investors file update showing 0% stake - Stock Titan
JATT II Acquisition Corp (JATT) reports 6.23% stake held by Great Point - Stock Titan
Atika Capital (JATT) discloses 5.1% beneficial stake in JATT II Acquisition Corp. - Stock Titan
Balyasny Asset Management (JATT) discloses 6.23% holding in JATT II common stock - Stock Titan
Janus Henderson Group (JATT) discloses 6.2% beneficial stake in JATT II - Stock Titan
JATT II Acquisition Corp. (JATT) plans Talawar merger backed by $225M PIPE - Stock Titan
JATT II Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
VSCTF Stock Price and Chart — OTC:VSCTF - TradingView
COPL|Copley Acquisition Corp|Price:10.480|Chg%:+0.010 - TradingKey
JATT II Acquisition Corp Revenue Breakdown – NASDAQ:JATT - TradingView
FACT|FACT II Acquisition Corp|Price:10.660|Chg%:+0.010 - TradingKey
BBCQ|Bleichroeder Acquisition II Units|Price:10.170| - TradingKey
MACI|Melar Acquisition Corp I|Price:10.910|Chg%:+0.010 - TradingKey
ASPC|A SPAC III Acquisition Corp|Price:10.542|Chg%:-0.098 - TradingKey
SPEG|Silver Pegasus Acquisition Corp|Price:10.300| - TradingKey
WTG|Wintergreen Acquisition Corp|Price:10.490|Chg%:+0.020 - TradingKey
FSHP|Flag Ship Acquisition Corp|Price:11.110| - TradingKey
JATT|JATT II Acquisition Ord Shs|Price:13.290|Chg%:+1.080 - TradingKey
ENHA|A Paradise Acquisition Ord Shs Class A|Price:2.650|Chg%:+0.020 - TradingKey
Talawar Therapeutics Appoints Steve Migausky as Chief Legal and Administrative Officer - PR Newswire
Jatt Ventures Ii L.p. Net Worth (2026) - GuruFocus
Biotech-Focused Hedge Funds Back Talawar’s Fast Moving SPAC Merger - Institutional Investor
JATTJatt II Acquisition Corp Revenue Breakdown - Finviz
JATT II Acquisition (JATT) sponsor forfeits 225,000 shares after over-allotment expiry - Stock Titan
JATT II Acquisition Corp. (JATT) sponsor forfeits 225,000 Ordinary Shares - Stock Titan
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - AOL.com
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger - Yahoo Finance
Price to book forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Talawar (NASDAQ: TLWR) to Merge with JATT II; $285M Expected - Stock Titan
Price to sales forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Price to earnings forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Talawar Therapeutics and JATT II Announce $285M Merger to Advance Bispecific Antibody for Atopic Dermatitis - Minichart
Talawar–JATT II deal includes $225M PIPE (NASDAQ: JATT) - Stock Titan
Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone disease - Endpoints News
Talawar Tx launches as publicly traded biotech - The Pharma Letter
Enterprise value to revenue forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Enterprise value to EBIT forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
JATT II Acquisition to Merge With Talawar Tx; JATT to Become Subsidiary in SPAC Deal - TradingView
Talawar, JATT II (Nasdaq: JATT) unveil $225M PIPE-backed biotech merger - Stock Titan
Talawar Therapeutics To Go Public Through A SPAC Deal With JATT II Acquisition - Pulse 2.0
JATT II Acquisition, Talawar Therapeutics announce combination agreement - TipRanks
Press Release: Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - Moomoo
Talawar Tx Inc. entered into a definitive business combination agreement to acquire JATT II Acquisition Corp. from JATT Ventures II L.P. in a reverse merger transaction. - marketscreener.com
JATT II ACQUISITION CORP (JATT) Stock Chart - ChartMill
OCAC.U Stock Fund Price and Chart — BOATS:OCAC.U - TradingView
JATT Price Today: JATT II Acquisition Corp. Stock Price, Quote & Chart | MEXC - MEXC Exchange
BermudaAppleby Advises Amanat Acquisition In Its USD75M Initial Public Offering - Mondaq
JATT II Acquisition Corp 2026 Q1 SEC Filing: Financials, Management Discussion, and Regulatory Disclosures - Minichart
JATT II Acquisition Corp. 1Q 2026: Net income $(68,793), EPS $(0.05) — 10-Q Summary - TradingView
Jatt Ii Acquisition Corp (JATT) 재무 분석
Jatt Ii Acquisition Corp (JATT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.95%
0.55%
자본화:
|
볼륨(24시간):